<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

Detroit 562

Description

Detroit 562 (Pharyngeal Cancer CDX Model) 

The Detroit 562 cell line was derived from a metastatic pharyngeal carcinoma. It is classified as a head and neck squamous cell carcinoma (HNSCC) model. Detroit 562 is widely used in studies of upper aerodigestive tract cancers. Its reproducible biology makes it valuable for evaluating therapies in HNSCC. 

Key Features: 

  • Derived from pharyngeal squamous cell carcinoma. 
  • Represents HNSCC biology. 
  • Maintains epithelial morphology. 
  • Consistent tumorigenicity in xenografts. 

Applications: 
Detroit 562 is applied in testing novel therapies for HNSCC. It supports biomarker discovery and evaluation of EGFR-targeted agents. Researchers use it to study mechanisms of tumor progression in head and neck cancers. Its reproducibility makes it useful in preclinical oncology pipelines.

Details
Tumor Type
Pharyngeal
Tumor Subtype
Pharyngeal carcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
PIK3CA
Mutation: p.H1047R
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic & Likely Pathogenic & Pathogenic
TP53
Mutation: p.R175H
Effect: Missense Variant
Impact: Not Provided & Likely Pathogenic & Pathogenic
Expression Data
Growth Curve
View on Lumin